Skip to main
SLN

Silence Therapeutics (SLN) P/E Ratio

P/E Ratio as of Feb 3, 2026: -2.90

Average-3.26
Median-3.33
Minimum-3.55
Maximum-2.88
-2.90
0.78 (21.20%)past month
The P/E ratio for Silence Therapeutics (SLN) is -2.90 as of Feb 3, 2026. This represents a decrease of -7.05% compared to its 12-month average P/E ratio of -3.12. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.

Silence Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)

Silence Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Silence Therapeutics to industry peers.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Silence Therapeutics (SLN) P/E Ratio Historic Data

DateStock priceP/E ratio
Dec 1, 2025$6.59-3.94
Nov 3, 2025$6.61-3.95
Oct 1, 2025$5.10-3.05
Sep 2, 2025$4.77-2.85
Aug 1, 2025$6.17-3.69
Jul 1, 2025$5.92-3.54
Jun 2, 2025$5.73-3.43
May 1, 2025$4.01-2.40
Apr 1, 2025$2.42-1.45
Mar 3, 2025$4.32-2.58
Feb 3, 2025$5.06-3.03
Jan 2, 2025$7.19-4.30

Silence Therapeutics (SLN) End of Year P/E Ratio

DateP/E ratioChange
2026-2.90-20.33%
2025-3.64-11.65%
2024-4.12-66.01%
2023-12.12+45.32%
2022-8.34-36.14%
2021-13.06

FAQs About Silence Therapeutics (SLN) P/E ratio

The latest P/E ratio of Silence Therapeutics (SLN) is -2.90, as of Feb 3, 2026. This is calculated based on its current stock price and earnings per share (EPS).

Silence Therapeutics’s last 12-month average P/E ratio is -3.12, compared to its current P/E ratio of -2.90. This reflects a decrease of -7.05%.

Silence Therapeutics’s current P/E ratio of -2.90 is lower than its last 12-month average P/E of -3.12. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.

Silence Therapeutics’s average P/E ratio over the last 3 years is -7.67. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.

Silence Therapeutics’s average P/E ratio over the last 5 years is -8.8. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.

Silence Therapeutics (SLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.